IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
-4.43%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$307M
AUM Growth
+$307M
(-12%)
Cap. Flow
+$18.2M
Cap. Flow
% of AUM
5.93%
Top 10 Holdings %
Top 10 Hldgs %
39.15%
Holding
181
New
26
Increased
23
Reduced
31
Closed
32
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Akero Therapeutics
AKRO
|
$9.92M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.62M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$8.53M |
| 5 |
Vaxcyte
PCVX
|
$7.55M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$6.57M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$6.3M |
| 3 |
Avalo Therapeutics
AVTX
|
$6.17M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$4.91M |
| 5 |
BridgeBio Pharma
BBIO
|
$4.32M |
Sector Composition
| 1 | Healthcare | 95.44% |
| 2 | Consumer Staples | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Rocket Pharmaceuticals
RCKT
$358M
| $1.48M | 0.18% |
221,911
| – | – |
|
52
Ventyx Biosciences
VTYX
$184M
| $1.4M | 0.17% |
1,217,590
+125,000
| +11% | +$144K |
|
53
Arcus Biosciences
RCUS
$1.24B
| $1.28M | 0.16% |
163,363
-215,000
| -57% | -$1.69M |
|
54
Delcath Systems
DCTH
$381M
| $1.28M | 0.16% |
100,365
| – | – |
|
55
Sangamo Therapeutics
SGMO
$161M
| $1.22M | 0.15% |
1,860,179
| – | – |
|
56
Viking Therapeutics
VKTX
$3.02B
| $1.21M | 0.15% |
+50,000
| New | +$1.21M |
|
57
Teladoc Health
TDOC
$1.37B
| $1.19M | 0.15% |
+150,000
| New | +$1.19M |
|
58
Alector
ALEC
$282M
| $1.17M | 0.14% |
950,000
| – | – |
|
|
OKUR
59
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $1.09M | 0.13% |
253,754
| – | – |
|
60
Nuvation Bio
NUVB
$1.08B
| $1.09M | 0.13% |
619,258
+535,851
| +642% | +$943K |
|
61
Nektar Therapeutics
NKTR
$543M
| $1.07M | 0.13% |
1,579,528
-449,500
| -22% | -$306K |
|
62
Tourmaline Bio
TRML
$645M
| $1.03M | 0.13% |
67,927
| – | – |
|
63
Immunic
IMUX
$79.4M
| $996K | 0.12% |
914,170
-700,000
| -43% | -$763K |
|
64
Terns Pharmaceuticals
TERN
$651M
| $851K | 0.1% |
308,491
| – | – |
|
65
Solid Biosciences
SLDB
$448M
| $851K | 0.1% |
+230,000
| New | +$851K |
|
66
89bio
ETNB
$1.37B
| $727K | 0.09% |
+100,000
| New | +$727K |
|
67
Olema Pharmaceuticals
OLMA
$432M
| $722K | 0.09% |
191,994
+100,000
| +109% | +$376K |
|
68
Veru
VERU
$48.5M
| $699K | 0.09% |
1,425,239
+480,000
| +51% | +$235K |
|
69
Lexicon Pharmaceuticals
LXRX
$392M
| $653K | 0.08% |
1,417,952
-132,048
| -9% | -$60.8K |
|
70
Monte Rosa Therapeutics
GLUE
$309M
| $634K | 0.08% |
136,575
-175,000
| -56% | -$812K |
|
|
PTHS
71
Pelthos Therapeutics Inc.
PTHS
$84.6M
| $626K | 0.08% |
+440,849
| New | +$626K |
|
72
Pyxis Oncology
PYXS
$91.2M
| $601K | 0.07% |
613,253
| – | – |
|
73
Inhibrx
INBX
$403M
| $589K | 0.07% |
42,122
| – | – |
|
74
Fulcrum Therapeutics
FULC
$353M
| $576K | 0.07% |
200,096
| – | – |
|
|
SWTX
75
DELISTED
SpringWorks Therapeutics
SWTX
| $552K | 0.07% |
12,519
-25,000
| -67% | -$1.1M |
|